<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146175">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742286</url>
  </required_header>
  <id_info>
    <org_study_id>CLDK378X2103</org_study_id>
    <secondary_id>2012-002074-31</secondary_id>
    <nct_id>NCT01742286</nct_id>
  </id_info>
  <brief_title>Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)</brief_title>
  <official_title>A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the maximum tolerated dose of LDK378 as a single
      agent, assess safety, tolerability and anti-tumor activity and characterize single and
      multiple-dose pharmacokinetics when administered orally to pediatric patients with
      ALK-activated tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LDK378 is a novel inhibitor of ALK that is active in a broad range of ALK-activated tumor
      models, including models driven by mutated versions of ALK known to be resistant to
      crizotinib, and by ALK gene amplification.

      The primary purpose of this study is to determine the maximum tolerated dose and/or
      recommended dose for expansion in pediatric patients, and to delineate a clinical dose to be
      used in any future pediatric studies. This study will also assess the safety, tolerability,
      PK and preliminary evidence of antitumor activity of LDK378 in pediatric patients with
      neuroblastoma, and other ALK-activated tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence rate of Dose Limiting Toxicities (DLT)</measure>
    <time_frame>up to day 21 after the patient's first dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>cycle = within the first 21 days of patient's first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse events</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory values</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments of physical examinations</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments of vital signs and electrocardiograms</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration time profiles</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the anti-tumor activity of LDK378</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the anti-tumor activity of LDK378</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the anti-tumor activity of LDK378 as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in disease burden in patients with lymphoma</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the anti-tumor activity of LDK378 as per International Working Group (IWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with serious adverse events</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameter: AUClast</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUCtau</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmin</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmax</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tmax</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Racc</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: t1/2</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: acc</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anaplastic Lymphoma Kinase (ALK)</condition>
  <arm_group>
    <arm_group_label>LDK378</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent LDK378</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDK378</intervention_name>
    <description>LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via NG/G tube</description>
    <arm_group_label>LDK378</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with a locally advanced or metastatic malignancy that has progressed
             despite standard therapy, or for which no effective standard therapy exists

          -  Age  ≥ 12 months and ≤ 17 years

          -  The tumor must carry a genetic alteration of ALK

          -  Patients must have evaluable or measurable disease

        Exclusion criteria:

          -  Symptomatic central nervous system (CNS) metastases who are neurologically unstable
             or require increasing doses of steroids or local CNS-directed therapy (such as
             radiotherapy, surgery or intrathecal chemotherapy) to control their CNS disease

          -  Clinically significant, uncontrolled heart disease

          -  Inadequate end organ function as defined by specified laboratory values

          -  Use of medications that are known to be strong inhibitors or inducers of CYP3A4/5
             that cannot be discontinued at least 1 week prior to start of treatment with LDK378
             and for the duration of the study

          -  Use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be
             discontinued at least 1 week prior to start of treatment with LDK378 and for the
             duration of the study.

          -  History of interstitial lung disease or interstitial pneumonitis, including
             clinically significant radiation pneumonitis

          -  Medications with a known risk of prolongation of QT interval
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA LeConte Location</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta Dept of Oncology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Garrett</last_name>
      <phone>404-785-3535</phone>
      <email>katherine.garrett@choa.org</email>
    </contact>
    <investigator>
      <last_name>Howard Katzenstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute Dept of Onc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Yang</last_name>
      <phone>617-582-7169</phone>
      <email>Mei_yang@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Shusterman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center SC - 7</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginia Cabezon</last_name>
      <phone>646-888-5716</phone>
      <email>cabezonv@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Shakeel Modak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center Dept of Oncology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Doughman</last_name>
      <phone>513-636-9419</phone>
      <email>renee.doughman@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brian Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude's Children's Research Hospital Dept of Oncology</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Letitia Anne Williams</last_name>
      <phone>+1 901 595 2388</phone>
      <email>letitia.williams@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Pappo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital Dept of Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Tucker-Hall</last_name>
      <phone>832-824-4570</phone>
      <email>mxtucker@txch.org</email>
    </contact>
    <investigator>
      <last_name>Eric Schafer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2130</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>November 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric, anaplastic lymphoma kinase, ALK-activated tumors, neuroblastoma, rhabdomyosarcoma, anaplastic large-cell lymphoma, inflammatory myofibroblastic tumor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
